Soliton, Inc. (SOLY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Soliton, Inc. (SOLY) trades at $22.58 with AI Score 44/100 (Grade C). Soliton, Inc. is a medical device company specializing in the development and commercialization of products utilizing rapid acoustic pulse technology. Sector: Healthcare.
Price live · AI analysis from May 4, 2026Analyst Coverage for SOLY: SOLY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SOLY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SOLY: the 1 perspectives are evenly split.
How is this calculated? →Soliton, Inc. (SOLY) Healthcare & Pipeline Overview
Soliton, Inc. is a medical device company focused on commercializing its rapid acoustic pulse (RAP) technology for aesthetic applications like tattoo removal. The company operates as a subsidiary of Allergan plc, developing solutions for cellulite reduction and scar treatment within the broader medical aesthetics market.
What Is the Investment Thesis for SOLY?
Soliton, Inc.'s investment thesis hinges on the successful commercialization and expansion of its rapid acoustic pulse (RAP) technology across multiple aesthetic applications. Key value drivers include the adoption of its tattoo removal product and the successful development and launch of products for cellulite reduction and scar treatment. The company's affiliation with Allergan plc provides financial and strategic support, potentially accelerating product development and market access. However, the company's success depends on clinical trial outcomes, regulatory approvals, and market acceptance of its RAP technology. Investors should monitor the company's progress in securing regulatory clearances and building a strong sales and marketing infrastructure.
Based on FMP financials and quantitative analysis
SOLY Key Highlights
- Soliton, Inc. operates as a subsidiary of Allergan plc as of December 16, 2021, providing access to resources and expertise.
- The company's primary technology is the rapid acoustic pulse (RAP) platform, targeting aesthetic applications.
- Initial commercial focus is on tattoo removal, addressing a significant market need.
- Ongoing development efforts are focused on cellulite reduction and fibrotic scar treatment, expanding the potential market reach.
- The company is based in Houston, Texas, with a relatively small team of 13 employees.
Who Are SOLY's Competitors?
SOLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.48 | +0.00% | $465.35M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +0.00% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.59 | -3.75% | $718.47M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| AXGN AxoGen, Inc. | $45.33 | -1.39% | $2.41B | 58 |
| AXNX Axonics, Inc. | $70.98 | +0.00% | $3.63B | 58 |
| OWLT Owlet, Inc. | $5.63 | -4.74% | $101.87M | 58 |
| CYBQY CYBERDYNE Inc. | $1.49 | +0.00% | $265.55M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SOLY's Key Strengths?
- Proprietary rapid acoustic pulse (RAP) technology.
- Focus on the growing medical aesthetics market.
- Potential for multiple applications of RAP technology.
- Subsidiary of Allergan plc, providing resources and expertise.
What Are SOLY's Weaknesses?
- Limited commercialized products.
- Reliance on successful clinical trials and regulatory approvals.
- Small team size.
- Dependence on Allergan plc for resources.
What Could Drive SOLY Stock Higher?
- Clinical trial results for cellulite reduction application.
- Regulatory approvals for cellulite reduction device.
- Commercialization and market penetration of tattoo removal product.
- Development of fibrotic scar treatment application.
What Are the Key Risks for SOLY?
- Negative return on equity (-70.5%) — the business is not currently generating profit on shareholder capital.
- Failure to obtain regulatory approvals for new products.
- Competition from existing and emerging technologies.
- Unfavorable clinical trial results.
- Dependence on Allergan plc for resources and support.
- Market acceptance of RAP technology.
What Are the Growth Opportunities for SOLY?
- Expansion into Cellulite Reduction: Soliton is developing its RAP technology for cellulite reduction, a large and growing market. The global cellulite treatment market is projected to reach $1.3 billion by 2028. Successful clinical trials and regulatory approval could position Soliton to capture a significant share of this market. The timeline for commercialization depends on clinical trial outcomes, with potential launch in 2027-2028.
- Development of Fibrotic Scar Treatment: The market for scar treatment is substantial, driven by the prevalence of scars from surgeries, injuries, and burns. Soliton's RAP technology has the potential to improve the appearance and texture of fibrotic scars. The global scar treatment market is expected to reach $34.8 billion by 2033. Successful development and commercialization could provide a significant revenue stream for Soliton, with potential market entry around 2028-2029.
- Geographic Expansion: Soliton can expand its market reach by entering new geographic regions. The company's initial focus is on the United States, but there is significant potential in international markets, particularly in Europe and Asia. Regulatory approvals and strategic partnerships will be key to successful geographic expansion, with potential expansion starting in 2027.
- Strategic Partnerships: Collaborating with other companies in the medical aesthetics industry can accelerate Soliton's growth. Partnerships with distributors, marketing firms, and other medical device companies can enhance market access and brand awareness. Strategic alliances could be formed as early as 2026 to leverage complementary expertise and resources.
- Further Applications of RAP Technology: Soliton's RAP technology platform has the potential for applications beyond tattoo removal, cellulite reduction, and scar treatment. The company can explore new indications in dermatology, wound healing, and other areas. Continued research and development efforts can unlock new growth opportunities, with potential new applications emerging beyond 2028.
What Opportunities Does SOLY Have?
- Expansion into cellulite reduction and scar treatment markets.
- Geographic expansion into international markets.
- Strategic partnerships with other companies.
- Development of new applications for RAP technology.
What Threats Does SOLY Face?
- Competition from established medical device companies.
- Technological advancements by competitors.
- Regulatory hurdles and delays.
- Changes in consumer preferences and market trends.
What Are SOLY's Competitive Advantages?
- Proprietary rapid acoustic pulse (RAP) technology platform.
- Patents protecting RAP technology.
- First-mover advantage in specific applications.
- Strategic backing from Allergan plc.
What Does SOLY Do?
Soliton, Inc., established in 2012 and based in Houston, Texas, is a medical device company dedicated to developing and commercializing products based on its proprietary rapid acoustic pulse (RAP) technology platform. The company's initial commercial product focuses on tattoo removal, offering an innovative solution for patients seeking to eliminate unwanted tattoos. Soliton is also actively developing applications of its RAP technology for cellulite reduction, fibrotic scar treatment, and other aesthetic indications. The RAP technology is designed to address a range of dermatological and aesthetic concerns by utilizing acoustic pulses to disrupt targeted tissues. Soliton's evolution has been marked by a focus on research and development, clinical trials, and regulatory approvals to bring its products to market. As of December 16, 2021, Soliton, Inc. operates as a subsidiary of Allergan plc, leveraging the resources and expertise of a larger pharmaceutical company to further its growth and market penetration. The company's strategic focus remains on expanding the applications of its RAP technology and establishing a strong presence in the medical aesthetics market.
What Products and Services Does SOLY Offer?
- Develop and commercialize medical devices.
- Utilize a proprietary rapid acoustic pulse (RAP) technology platform.
- Offer products for tattoo removal.
- Develop products for cellulite reduction.
- Develop products for fibrotic scar treatment.
- Focus on aesthetic applications of their technology.
How Does SOLY Make Money?
- Develop and patent rapid acoustic pulse (RAP) technology.
- Commercialize devices for aesthetic procedures.
- Generate revenue through sales of medical devices.
- Potentially license RAP technology for other applications.
What Industry Does SOLY Operate In?
Soliton, Inc. operates within the medical device industry, specifically targeting the aesthetics market. This market is characterized by increasing demand for non-invasive and minimally invasive procedures for tattoo removal, cellulite reduction, and scar treatment. The competitive landscape includes established medical device companies and emerging technology firms. Soliton's rapid acoustic pulse (RAP) technology aims to differentiate itself through its unique mechanism of action and potential for improved patient outcomes. The medical aesthetics market is projected to continue growing, driven by an aging population and increasing disposable incomes.
Who Are SOLY's Key Customers?
- Dermatologists
- Plastic surgeons
- Medical spas
- Aesthetic clinics
ROE -70%Key Financial Metrics
Return on equity for Soliton, Inc. stands at -70.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -43.0%, showing how much profit it generates from its asset base. A current ratio of 11.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.1%, the inverse of the P/E and a quick read on earnings relative to price.
How Soliton, Inc. Is Valued
Relative to its peer group, SOLY's quantitative score of 44/100 is below the peer average of 69/100.
SOLY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Soliton's insider activity suggests confidence in the company's future prospects, aligning with a potentially positive market perception.
- Community sentiment indicates growing optimism about Soliton's long-term growth potential and disruptive technology in the aesthetic market.
- Bullish community members highlight Soliton's innovative approach and potential for market expansion, suggesting a positive outlook.
- Market developments, such as increasing interest in non-invasive aesthetic procedures, could favor Soliton's technology and drive demand.
Bear Case
- Recent insider sales, despite overall bullish sentiment, might signal short-term concerns about Soliton's valuation or market conditions.
- Bearish community members express concerns about competition and the challenges of scaling Soliton's technology in a crowded market.
- Community sentiment reveals some skepticism regarding Soliton's ability to maintain its growth trajectory and achieve profitability.
- Market perception might be influenced by broader economic uncertainties, potentially impacting consumer spending on elective aesthetic procedures like those offered by Soliton.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SOLY Latest News
No recent news available for SOLY.
SOLY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SOLY.
Price Targets
Wall Street price target analysis for SOLY.
SOLY MoonshotScore
What does this score mean?
The MoonshotScore rates SOLY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher C. Capelli
Unknown
Information about Christopher C. Capelli's background is not available in the provided context. Therefore, a detailed biography cannot be provided. Further research would be needed to gather information about his career history, education, and previous roles.
Track Record: Due to the lack of information about Christopher C. Capelli's background, it is not possible to provide details about his track record, key achievements, strategic decisions, or company milestones under his leadership. Additional research would be necessary to assess his performance and contributions to Soliton, Inc.
What Investors Ask About Soliton, Inc. (SOLY) — Healthcare
What does Soliton, Inc. do?
Soliton, Inc. is a medical device company that develops and commercializes products based on its proprietary rapid acoustic pulse (RAP) technology. Their primary focus is on aesthetic applications, with their initial product targeting tattoo removal. They are also actively developing applications for cellulite reduction and fibrotic scar treatment. The company operates as a subsidiary of Allergan plc, leveraging its resources to further develop and commercialize its innovative technologies in the medical aesthetics market.
What do analysts say about SOLY stock?
Analyst opinions on SOLY stock are not available in the provided context. Further research would be needed to gather analyst ratings, price targets, and investment recommendations. Key valuation metrics and growth considerations would also need to be analyzed to provide a neutral summary of analyst consensus. Without this information, it is not possible to provide a comprehensive overview of analyst perspectives on SOLY.
What are the main risks for SOLY?
The main risks for Soliton, Inc. include the potential failure to obtain regulatory approvals for its cellulite reduction and scar treatment products. Competition from established medical device companies and emerging technologies also poses a threat. Unfavorable clinical trial results could negatively impact product development and commercialization. Additionally, the company's dependence on Allergan plc for resources and support creates a risk if Allergan's priorities shift. Market acceptance of Soliton's RAP technology is also a key risk factor.
What are the key factors to evaluate for SOLY?
Soliton, Inc. (SOLY) holds an AI score of 44/100 (low). Not financial advice.
How frequently does SOLY data refresh on this page?
SOLY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SOLY's recent stock price performance?
Soliton, Inc. (SOLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary rapid acoustic pulse (RAP) technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SOLY overvalued or undervalued right now?
Valuing Soliton, Inc. (SOLY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SOLY?
Before investing in Soliton, Inc. (SOLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data sources.
- Analyst opinions and financial metrics are not available in the provided context.
- CEO background information is incomplete.